Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fovista + Avastin versus Avastin alone in neovascular age-related macular degeneration
2015-000518-23Phase 2Terminated
- Sponsor
- IVERIC bio
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in exudative macular degeneration, subfoveal choroidal neovascularization (CNV) and age-related macular degeneration (AMD) comparing Fovista + Avastin with Avastin monotherapy (2 arms). Primary endpoint: Mean change in visual acuity from baseline at Month 18. Started Jun 2015; status: terminated.
02
Drugs
pegpleranibbevacizumab
03
Conditions
exudative macular degenerationsubfoveal choroidal neovascularization (CNV)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2015-000518-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000518-23.